journal article·2024-02

Targeting Hypoxic Tumor Plasticity for Recapturing Photodynamic‐Immunotherapy Sensitivity via Fluorinated Polysensitizers

Lingpu Zhang, Lin Tang, Changyuan Yu, Haihua Xiao, Chaoyong Liu

Advanced Functional Materials· Volume 34· Issue 8
Publisher page

Abstract

Abstract Metabolic reprogramming is a key characteristics of tumor cells, mainly manifested by abnormal metabolism and tumor hypoxia. Here, the design of PolyFBODIPY characterized by the presence of BODIPY photosensitizers, fluorinated aliphatic chains as Oxygen affinity materials, and reactive oxygen species‐sensitive thioketal linkers is reported. PolyFBODIPY subsequently self‐assembles into NP@PolyFBODIPY which is capable of delivering oxygen and photosensitizers simultaneously and generating ROS under light irradiation, resulting in rapid polymer degradation and nanoparticle dissociation via breaking ROS‐sensitive thiol ketal linkers. NP@PolyFBODIPY can target hypoxic tumor plasticity to reprogram metabolism for recapturing photodynamic‐immunotherapy sensitivity for completely inhibiting tumor growth on multi‐drug‐resistant patient‐derived lung cancer xenografts (PDXMDR). Moreover, NP@PolyFBODIPY‐mediated photodynamic‐immunotherapy activates antitumor immune responses and effectively inhibits tumor growth and lung metastasis on an orthotropic metastatic triple‐negative breast cancer model. Mechanistically, metabolomics and lipidomics analysis reveals that NP@PolyFBODIPY‐mediated photodynamic‐immunotherapy not only destroys the redox state of cancer cells, but also affects the metabolism of lipid, amino acid, and d‐glutamine, thereby finally promoting autophagy and apoptosis and inhibiting the proliferation of cancer cells. These results highlight the potential of clinical translation of NP@PolyFBODIPY in targeting hypoxic tumor plasticity via oxygen supply, which reprograms the cellular metabolism for recapturing photodynamic‐immunotherapy sensitivity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Beijing Advanced Innovation Center for Soft Matter Science and Engineering College of Life Science and Technology Beijing University of Chemical Technology Beijing 100029 P. R. China

Beijing National Laboratory for Molecular Science State Key Laboratory of Polymer Physics and Chemistry Institute of Chemistry Chinese Academy of Science Beijing 100190 China

Funding

National Natural Science Foundation of China

References (58)

Show source-provided references
1. 10.3390/ijms2123912510.3390/ijms21239125 ↗
2. 10.1038/s41419-020-03175-510.1038/s41419-020-03175-5 ↗
3. 10.1016/j.immuni.2015.09.00110.1016/j.immuni.2015.09.001 ↗
4. 10.1126/science.aaf440510.1126/science.aaf4405 ↗
5. 10.1016/j.cmet.2015.12.00610.1016/j.cmet.2015.12.006 ↗
6. 10.1038/nri.2017.10310.1038/nri.2017.103 ↗
7. 10.1038/nrc.2016.8410.1038/nrc.2016.84 ↗
8. 10.1038/nature1016910.1038/nature10169 ↗
9. Kang Z. Y. · Adv. Mater. · 2022 · 34
10. 10.1016/j.canlet.2020.07.00710.1016/j.canlet.2020.07.007 ↗
11. 10.3847/1538-4357/abe4d210.3847/1538-4357/abe4d2 ↗
12. 10.1021/acsnano.0c0772110.1021/acsnano.0c07721 ↗
13. 10.1172/JCI6974110.1172/JCI69741 ↗
14. 10.1038/s41571-019-0203-710.1038/s41571-019-0203-7 ↗
15. 10.1002/adma.20220382010.1002/adma.202203820 ↗
16. 10.1038/s41467-023-40826-510.1038/s41467-023-40826-5 ↗
17. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
18. 10.1038/s41467-021-24961-510.1038/s41467-021-24961-5 ↗
19. 10.1038/nrc107110.1038/nrc1071 ↗
20. 10.1002/adhm.20190099610.1002/adhm.201900996 ↗
21. 10.1002/anie.20180513810.1002/anie.201805138 ↗
22. 10.1021/cr500419810.1021/cr5004198 ↗
23. 10.1002/adhm.20160012110.1002/adhm.201600121 ↗
24. 10.1039/C6CS00271D10.1039/C6CS00271D ↗
25. 10.1039/C2CS35216H10.1039/C2CS35216H ↗
26. 10.1021/acsnano.1c0007610.1021/acsnano.1c00076 ↗
27. 10.1002/adma.20210059910.1002/adma.202100599 ↗
28. 10.1021/acs.nanolett.6b0236510.1021/acs.nanolett.6b02365 ↗
29. 10.1002/adma.20170142910.1002/adma.201701429 ↗
30. 10.1002/anie.20210218010.1002/anie.202102180 ↗
31. 10.1021/jacs.7b0555910.1021/jacs.7b05559 ↗
32. 10.1038/s41467-017-01050-010.1038/s41467-017-01050-0 ↗
33. 10.1039/C7CS00891K10.1039/C7CS00891K ↗
34. 10.1016/j.cmet.2015.08.00710.1016/j.cmet.2015.08.007 ↗
35. 10.1038/ncomms946810.1038/ncomms9468 ↗
36. 10.1021/acsami.9b1811210.1021/acsami.9b18112 ↗
37. 10.1172/JCI6723010.1172/JCI67230 ↗
38. 10.1016/j.cell.2015.11.01110.1016/j.cell.2015.11.011 ↗
39. 10.1021/acsnano.1c0003310.1021/acsnano.1c00033 ↗
40. 10.1021/acsnano.9b0942610.1021/acsnano.9b09426 ↗
41. 10.1021/acsnano.8b0437110.1021/acsnano.8b04371 ↗
42. 10.1002/adfm.20220971110.1002/adfm.202209711 ↗
43. 10.1002/marc.20210013010.1002/marc.202100130 ↗
44. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
45. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
46. 10.1038/nrc338010.1038/nrc3380 ↗
47. 10.1002/VIW.2020004210.1002/VIW.20200042 ↗
48. 10.1002/marc.20210005410.1002/marc.202100054 ↗
49. 10.1021/acs.bioconjchem.6b0043710.1021/acs.bioconjchem.6b00437 ↗
50. 10.1021/acs.jmedchem.0c0200610.1021/acs.jmedchem.0c02006 ↗
51. 10.1016/j.drudis.2006.07.00510.1016/j.drudis.2006.07.005 ↗
52. 10.1021/jo400769u10.1021/jo400769u ↗
53. 10.1039/D0NH00148A10.1039/D0NH00148A ↗
54. 10.1016/j.jhazmat.2018.05.01010.1016/j.jhazmat.2018.05.010 ↗
55. 10.1016/j.talanta.2021.12215010.1016/j.talanta.2021.122150 ↗
56. 10.1038/nrc167010.1038/nrc1670 ↗
57. 10.1111/joim.1208410.1111/joim.12084 ↗
58. 10.1002/adma.20221026710.1002/adma.202210267 ↗